Hormone-continuous monitoring sensors can reveal fertility disorders in both sexes

Research presented at the 28th European Congress of Endocrinology in Prague, Czechia, has suggested that men and women with apparently normal reproductive hormone levels may still have disrupted hormonal rhythms that could impair fertility

Men and women who appear hormonally normal in standard clinical tests may still have hidden disruptions in the timing and coordination of their reproductive hormones that could affect fertility, according to research which was presented at the 28th European Congress of Endocrinology in Prague, in May 2026.

The findings have suggested that reproductive health may depend not only on the quantity of key hormones in the bloodstream but also on the rhythm, timing and synchronisation of hormonal fluctuations across hours, days and the menstrual cycle. Researchers said that a wearable skin sensor patch, combined with artificial intelligence (AI), could help clinicians to detect endocrine dysfunction earlier and offer more personalised support to people who experience unexplained infertility.

Unexplained infertility affects about 15 to 30 per cent of couples and is diagnosed when standard investigations reveal no clear cause. In men, current tests for infertility or hypogonadism – defined clinically as low testosterone – often include a single morning serum testosterone measurement. In women, fertility assessment typically examines menstrual cycle characteristics and reproductive hormones such as luteinising hormone, follicle-stimulating hormone, oestradiol and progesterone.

However, reproductive hormones are not static markers. They are dynamic biological signals that rise and fall in regulated patterns throughout the day and across the menstrual cycle. Testosterone, for example, follows a diurnal rhythm, while female reproductive hormones act through finely coordinated feedback loops involving the hypothalamic, pituitary and ovarian systems. A single blood test may therefore miss clinically important disruption in hormonal timing.

In one study, Dr. Tinatin Kutchukhidze, from the University of Oxford examined 102 men in Georgia and the UK. The participants were aged 22 to 38 years and had normal morning total testosterone levels – measured at 12 to 35 nanomoles per litre – with or without infertility or symptoms of hypogonadism.

Kutchukhidze and colleagues studied the use a wearable AI-enabled skin sensor patches to measure testosterone levels every 15 minutes across four days. The team found that men with symptoms had significantly disrupted testosterone rhythms, despite standard laboratory tests which showed normal testosterone levels. These previously undetected rhythm abnormalities were also associated with reduced sperm concentration and symptoms of androgen deficiency.

“For the first time, we have been able to track androgen patterns in real time across several days with a novel, non-invasive, continuous, AI-driven testosterone monitoring patch, compatible with Android and iPhone mobile devices,” Kutchukhidze said.

“Previous research suggests that a normal morning testosterone level is sufficient to exclude clinically significant androgen deficiency. However, our findings challenge that assumption by demonstrating that men with normal serum testosterone may still exhibit marked disturbances in hormonal rhythmicity associated with reproductive dysfunction,” Kutchukhidze added.

According to the abstract, the study compared 54 men with infertility or hypogonadal symptoms with 48 age-matched healthy controls. Mean morning serum testosterone did not differ significantly between symptomatic men and controls, at 22.4 ± 3.1 compared with 23.1 ± 3.5 nanomoles per litre.

Continuous AI-assisted monitoring, however, revealed significant differences in androgen dynamics. Men with symptoms had lower diurnal amplitude than controls, at 5.2 ± 1.1 compared with 8.7 ± 1.4 nanomoles per litre.

The AI-derived rhythm indices predicted subclinical dysfunction with an area under the curve of 0.87, compared with 0.61 for static serum testosterone. In diagnostic research, the area under the curve is used to assess how well a test distinguishes between groups, with higher values to indicate stronger discrimination.

A second study by Kutchukhidze’s team examined female reproductive hormone rhythms. The researchers developed an AI-driven metric called Endocrine Rhythm Integrity to assess whether reproductive hormones changed in the correct pattern, at the correct time and in the correct relationship to one another across the menstrual cycle.

The team analysed data from 312 women aged 18 to 22 years who had self-reported regular menstrual cycles. Participants included fertile controls and women with unexplained infertility. The researchers assessed key reproductive hormones during the luteal phase, including luteinising hormone, follicle-stimulating hormone, oestradiol and progesterone. They also incorporated physiological data such as basal body temperature, heart rate and sleep patterns.

The study found that women with unexplained infertility had lower Endocrine Rhythm Integrity scores even when conventional hormone levels appeared normal. Lower scores predicted infertility and were also associated with a higher incidence of implantation failure.

“Our study reveals that a woman may have a seemingly healthy menstrual cycle and normal hormone levels but still experience hidden endocrine dysfunction that affects her ability to conceive,” said Kutchukhidze.

“Rather than analysing hormone levels as isolated values, Endocrine Rhythm Integrity evaluates whether reproductive hormones are changing in the correct pattern, at the correct time and in the correct relationship to one another across the menstrual cycle,” she added.

In the female study, mean cycle length did not differ significantly between fertile and infertile groups, at 28.9 ± 2.3 compared with 28.9 ± 2.5 days. Endocrine Rhythm Integrity scores, however, were lower in the infertility group, at 0.61 ± 0.12 compared with 0.78 ± 0.10. Disrupted endocrine rhythm integrity was observed in 64 per cent of infertile participants despite hormonally normal mid-luteal progesterone levels.

The metric independently predicted infertility status after adjustment for age, body mass index and anti-Müllerian hormone – a hormone made by reproductive tissues and best known for its use as a marker of ovarian reserve. Receiver operating characteristic analysis indicated that Endocrine Rhythm Integrity identified infertility more effectively than cycle length or single-time-point progesterone assessment. Lower Endocrine Rhythm Integrity scores were also associated with a higher incidence of implantation failure.

“Our AI-driven rhythm analyses were significantly better at identifying subclinical reproductive dysfunction than conventional testing, suggesting that both female and male endocrine disorders may not simply be disorders of hormone quantity, but rather disorders of hormonal timing, synchronisation and biological rhythm,” Kutchukhidze said.

The team will next assess whether the tool can reliably predict fertility outcomes across different reproductive conditions in larger and more diverse populations. Such work will be important because the current studies were observational and involved defined age groups. Wider validation would be needed before the technology could form part of routine fertility assessment.

“We aim to move fertility care toward predictive, rhythm-based reproductive medicine, where clinicians can identify dysfunction earlier, personalise interventions and improve outcomes before infertility becomes clinically evident,” said Kutchukhidze.

“If successful, this research could lead to the first clinically actionable tool for measuring endocrine-rhythm health and redefine how fertility is evaluated worldwide.

“Importantly, this technology could also be widely applied in transgender medicine, where hormone therapy currently relies on intermittent blood tests that may not reflect real-time hormonal dynamics.

“Our long-term goal is to establish wearable hormonal chronodiagnostics as a novel standard not only in reproductive medicine and personalised endocrinology but also in transgender healthcare, enabling more precise, adaptive and patient-centred management across diverse clinical settings,” she added.